| Program : Revamilast (GRC 4039) |
Phase I Complete |
|
|
| Target /Indication |
A (PDE) IV Inhibitor indicated for the treatment of Rheumatoid Arthritis, Multiple Sclerosis and other Inflammatory Pain |
| Highlights |
| |
|
After the withdrawal of Cox-2 inhibitors, there exists a huge void in therapy for orally available small molecules |
| |
|
Phase I trials complete. Phase II to be initiated for |
| |
|
Good safety profile to achieve higher exposure levels in humans and better therapeutic window |
|
| Market Opportunity |
| |
|
Rheumatoid Arthritis Market: $ 16 bn; > 20 mn patients
|
|
| Potential Peak Sales |
USD 3 bn worldwide
|
|
|
| |
| Program : Melogliptin (GRC 8200) |
Phase IIB Complete |
|
|
| Target /Indication |
A (DPP) IV Inhibitor indicated for Diabetes (Type II) |
| Highlights |
| |
|
Potential Best-in-Class in terms of safety and efficacy The molecule is expected to enter Phase III |
| |
|
DPP IV is one of the most promising treatment pathway to come up in the large and growing diabetes market |
| |
|
Currently being developed as monotherapy as well as combination therapy with other anti-diabetic molecules |
|
| Market Opportunity |
| |
|
125 mn patients worldwide / Market Size: USD 35 bn by 2015
|
|
| Potential Peak Sales |
USD 1 bn worldwide
|
|
|
| |
